Prescription drug spending by payer: Implications for managed care
Background: Brand-name prescription drugs are an important driver of prescription drug spending, but different payers may bear these costs differentially necessitating different policy goals for each payer. But little is known about how the top 10 selling drugs in the U.S. impact spending across pay...
Saved in:
Main Authors: | Yousef Chavehpour (Author), Rajesh Balkrishnan (Author), Joel E. Segel (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Changes in healthcare spending attributable to obesity and overweight: payer- and service-specific estimates
by: Eline van den Broek-Altenburg, et al.
Published: (2022) -
Branded prescription drug spending: a framework to evaluate policy options
by: Jeromie Ballreich, et al.
Published: (2017) -
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014) -
Book Review: Consumer-Driven Health Care: Implications for Providers, Payers, and Policymakers
by: Howard W. Houser Ph.D
Published: (2005) -
Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs
by: Epstein RS
Published: (2021)